Navigation Links
MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery

WARRENDALE, Pa., June 12 /PRNewswire/ -- MEDRAD, INC., has signed a distribution and co-marketing partnership agreement with PETNET Solutions, a fully owned subsidiary of Siemens Medical Solutions USA, Inc. The agreement will enable health care providers to inject Fluorodeoxyglucose (FDG) for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures in an innovative, new way. The partnership will leverage MEDRAD's soon to be introduced PET infusion system and multi-dose FDG packaging and delivery from PETNET Solutions. PET/CT Imaging has proven effective in diagnosing and staging certain forms of cancer.

(Logo: )

MEDRAD's PET infusion system, to be called Intego(TM), is designed to automatically extract a patient dose from a multi-dose vial and deliver it directly to the patient. The system is mobile and includes dosimetry, shielding, and a touchscreen interface -- all with precision, flexibility, and safety in mind.

PETNET Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with MEDRAD's new system.

Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Medical Solutions USA, Inc., commented, "In addition to our traditional delivery method, by providing FDG in multi-dose vials compatible with the MEDRAD PET infusion system across our extensive network, we have the opportunity to help improve the way FDG is being handled and delivered."

Alan Connor, director of global marketing for MEDRAD Molecular Imaging, said, "We are very pleased that PETNET Solutions is the first FDG provider to agree to provide FDG in a manner compatible with the Intego System across its entire network. From the beginning of this project, PETNET Solutions has been instrumental to the development of this system and is dedicated to providing the latest in safety and clinical performance to their customers."

MEDRAD will show the system at the annual Society of Nuclear Medicine (SNM) meeting in New Orleans, Louisiana, on June 13-16.


MEDRAD, INC., is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

About PETNET Solutions

PETNET Solutions, a fully owned subsidiary of Siemens Medical solutions, operates the largest PET radiopharmacy network with over 44 radiopharmacies and distribution centers at multiple locations that produce and distribute PET radiopharmaceuticals to hospitals, clinics, and research facilities for PET imaging.

Cautionary statement regarding forward-looking statement.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC., undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD(R) Revenues Grow 10 Percent in 2007
2. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
3. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
4. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
5. National Staff Nurses Union Endorses Obama for President; UAN Leaders Cite Obamas Commitment to Working Families, Health Care Solutions
6. Authentidate and EncounterCare Form ExpressMD Solutions Joint Venture to Provide Telehealth Vital Signs Monitoring Systems Designed to Improve Chronic Illness Care for Patients
7. NCPA Statement on Sen. Baucus Medicare Bill Inclusion of Solutions for Medicare and Medicaid Reimbursement Problems
8. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
9. SXC Health Solutions to provide technology services and support to major PBM
10. Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
11. Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: